PDYN and Huntington disease: Given the urgent need for surrogate endpoints in ongoing clinical trials for HD, PDYN- and PENK-derived peptides may be used together with neurofilament light chain protein (NfL) as biomarkers of disease severity that could be potentially influenced by future disease-modifying therapies [31, 32].